1

2
David Alan Owen, John Gary Montana, John Fraser Keily, Robert John Watson, Andrew Douglas Baxter: Hydroxamic and carboxylic acid derivatives having MMP and TNF inhibitory activity. Darwin Discovery, Saliwanchik Lloyd & Saliwanchik, September 12, 2000: US06118001 (10 worldwide citation)

Disclosed are hydroxamic and carboxylic acid derivatives which are useful inhibitors of matrix metalloproteinase and/or TNF.alpha.-mediated diseases, including degenerative diseases and certain cancers.


3
Duncan Robert Hannah, Hazel Joan Dyke, Robert John Watson, John Fraser Keily, Andrew Douglas Baxter: Hydroxamic and carboxylic acid derivatives. Darwin Discovery, Saliwanchik Lloyd & Saliwanchik, January 14, 2003: US06506773 (6 worldwide citation)

Pharmacologically active compounds are provided as well as pharmaceutical compositions and methods for treating cancer; inflammation; an autoimmune, infectious or ocular disease; or age-related macular degeneration in a mammal.


4

5
Duncan Robert Hannah, Hazel Joan Dyke, Robert John Watson, John Fraser Keily, Andrew Douglas Baxter: Hydroxamic and carboxylic acid derivatives. Darwin Discovery, Saliwanchik Lloyd & Saliwanchik, August 23, 2005: US06933306

Pharmacologically active compounds are provided as well as pharmaceutical compositions and methods for treating cancer; inflammation; an autoimmune, infectious or ocular disease; or age-related macular degeneration in a mammal.


6

7
Andrew Douglas Baxter, David Alan Owen, John Gary Montana, Robert John Watson, John Fraser Keily: Peptidyl compounds having MMP and TNF inhibitory activity. Darwin Discovery, Saliwanchik Lloyd & Saliwanchik, July 18, 2000: US06090840

The subject invention concerns mercaptoalkylacyl compounds of formula (I): ##STR1## The compounds of the subject invention can be used to inhibit matrix metalloproteinases and/or TNF.alpha.- and L-selectin sheddase-mediated diseases including degenerative diseases and cancers. The subject invention ...


8
Graham Michael Wynne, Kevin Doyle, Saleh Ahmed, An Hu Li, John Fraser Keily, Chrystelle Marie Rasamison, Neil Anthony Pegg, Imaad Saba, Claire Thomas, Don Smyth, Shazia Sadiq, Gary Newton, Graham Dawson, Andrew Phillip Crew, Arlindo Lucas Castelhano: (2-carboxamido)(3-amino)thiophene compounds. Osi Pharmaceuticals, September 23, 2004: US20040186124-A1

Compounds represented by Formula (I): 1 or a pharmaceutically acceptable salt or N-oxide thereof, wherein R1 is 2 R2 is 3 and R3 is C0-4alkyl, are useful in the treatment of cancer.


9
Duncan Robert Hannah, Hazel Joan Dyke, Robert John Watson, John Fraser Keily, Andrew Douglas Baxter: Hydroxamic and carboxylic acid derivatives. Saliwanchik Lloyd & Saliwanchik, A Professional Association, May 15, 2003: US20030092727-A1

Pharmacologically active compounds are provided as well as pharmaceutical compositions and methods for treating cancer; inflammation; an autoimmune, infectious or ocular disease; or age-related macular degeneration in a mammal.


10